Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Other Accumulated Expenses (2023 - 2025)

Regen BioPharma (RGBPP) has disclosed Other Accumulated Expenses for 3 consecutive years, with $99776.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 140.87% to $99776.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $99776.0, a 140.87% increase, with the full-year FY2025 number at $99776.0, up 375.12% from a year prior.
  • Other Accumulated Expenses was $99776.0 for Q4 2025 at Regen BioPharma, roughly flat from $99776.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $99776.0 in Q3 2025 to a low of $21000.0 in Q3 2024.
  • A 3-year average of $48352.6 and a median of $41423.0 in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: crashed 49.3% in 2024, then surged 375.12% in 2025.
  • Regen BioPharma's Other Accumulated Expenses stood at $41423.0 in 2023, then changed by 0.0% to $41423.0 in 2024, then soared by 140.87% to $99776.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Other Accumulated Expenses are $99776.0 (Q4 2025), $99776.0 (Q3 2025), and $21000.0 (Q2 2025).